Biosency has raised funds for further development
Biosency has completed a fundraising to develop a software for predictive diagnosis.
Biosency is a French MedTech company focused on changing the way clinicians and patients manage chronic obstructive pulmonary disease (COPD). The company provides innovative, connected and patient-focused remote monitoring solutions to analyze long-term trends of vital signs which are of critical importance to reduce readmission rates by adjusting medication.
Oaklins’ team in France acted as the exclusive advisor to Biosency.
Talk to the deal team
Related deals
Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Learn moreA group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreShield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Learn more